When technology transfer happens

Technology transfer happens at three points in a biologic's life, and each needs its own protocol. The first is development to GMP: a process defined in bench-top and pilot bioreactors moves into a clinical suite. The second is site to site: a clinical process moves to a commercial facility, or a product changes CDMO. The third is R&D to quality control: methods developed alongside the process are handed to the QC laboratory that will release batches.

The three differ in what changes. Development to GMP changes scale, equipment class and documentation standard. Site to site changes equipment, utilities, suppliers and people, often at constant scale. R&D to QC changes analysts, instruments and data systems, with the method held constant.

Timing sets the regulatory consequence. A transfer before pivotal trials is managed through development reports. A transfer after PPQ or approval is a change under ICH Q5E and ICH Q12, and the protocol must also generate comparability data.

Regulatory references: ICH Q10, WHO technology transfer guidance, ISPE Good Practice Guide

No single regulation prescribes a technology transfer validation protocol, so the protocol borrows from three sources. ICH Q10 (2008) names technology transfer as a lifecycle stage whose goal is to transfer product and process knowledge between development and manufacturing, and within or between manufacturing sites. Its knowledge, change and risk management elements are the protocol's backbone.

WHO's guideline, published as Annex 4 of Technical Report Series 1044 (2022), is the most prescriptive public document. It replaced the 2011 version in TRS 961 Annex 7 and covers organization, premises and equipment, documentation, process transfer, analytical transfer and cleaning.

The ISPE Good Practice Guide, 3rd edition (2018), adds the project-management layer: gap analysis templates, a transfer plan, and the "process description" document that travels between sites. For analytical transfer, USP <1224> and EU GMP Chapter 6, paragraphs 6.37 to 6.41, define the acceptable approaches and minimum protocol content.

Protocol structure

A complete technology transfer validation protocol has eight sections, and the acceptance criteria section decides whether the transfer can be closed.

Sections 3, 4 and 6 are linked. Every gap in section 3 gets a risk rank in section 4, and every high-risk item becomes an acceptance criterion in section 6. Break that chain and the document is a checklist, not a validation protocol.

Process transfer: comparing CPPs and CQAs between sending and receiving sites

Process transfer succeeds when the receiving site reproduces the critical process parameters and the resulting critical quality attributes within the sending site's demonstrated range. The protocol needs two data sets before the first run: the sending site's CPP ranges and CQA history, and the receiving site's equipment capability.

Scale and geometry decide which parameters can be held constant. Moving from a 50 L pilot vessel to a 2,000 L train, power per volume and kLa cannot both be matched, so the protocol states which is held and justifies it with scale-down data. Column diameter changes while bed height and residence time are held, so loading is expressed in grams per liter of resin. UF area scales with batch mass, so the comparison uses load per square meter and flux.

Engineering batches test these choices before PPQ. One at the receiving scale is common; two are justified when the bioreactor type or a chromatography resin changes. With a qualified scale-down model, part of the verification can run at bench scale.

Analytical method transfer: comparative testing, co-validation, revalidation

Method transfer must be completed before the process transfer runs are tested, because results from an untransferred method cannot support an acceptance criterion. USP <1224> describes four routes; EU GMP Chapter 6, paragraphs 6.37 to 6.41, sets the minimum protocol and report content.

• Comparative testing. Both laboratories test the same homogeneous samples, usually two or three lots, against pre-set limits; the default for release and stability methods.
• Co-validation. The receiving laboratory takes part in the original ICH Q2(R2) validation, generating the intermediate precision data. This fits a development-to-GMP transfer before validation.
• Revalidation. The receiving laboratory repeats some or all validation parameters, used when the method changes platform or no homogeneous samples exist.
• Transfer waiver. Justified only for compendial methods or methods the receiving site already runs on a comparable product.

Acceptance criteria are set from the method's validated precision, not from the specification. For a quantitative purity method, the difference between laboratory means and the pooled %RSD are compared with limits from the intermediate precision study. For potency assays, the ratio of relative potencies and its confidence interval are tested against an equivalence margin. Limit and identity tests are assessed as concordance.

Method transfer protocols fail most often on reagents and reference standards. The protocol should list reference standard, reagent and column lots, and both laboratories should use the same lots.

Documentation and sign-off

A transfer is closed by a report that states, against each acceptance criterion, whether it was met, approved by QA at both sites. Inspectors ask for it when a product moves between facilities, and it feeds the PPQ protocol and the Module 3 process description.

The minimum document set that travels with a technology transfer is the process description with CPP ranges and in-process controls, reference batch records, the bill of materials with supplier and grade, analytical methods with validation reports, cleaning and hold-time data, and stability data for intermediate holds. The receiving site converts these into its own master batch records and SOPs, and the differences are reviewed.

Sign-off follows a sequence: method transfer reports approved; engineering batch reports approved; deviations closed or risk-accepted by QA; the transfer report approved; formal release to PPQ or routine manufacture. A transfer that enters PPQ with open deviations carries them into the validation record.